• achieve total compliance with regulatory deadlines for completion of relevant procedures and applications and updating of the scientific output (e.g. product information and the EPAR) • optimise the management and monitoring of an increasing amount of safety information relating to centrally authorised medicinal products through close collaboration with CPMP, Member States and European pharmacovigilance experts • further streamline the management of referrals dealing with safety concerns for nationally authorised products and respect deadlines for the completion of such referral procedures • further strengthen collaboration and communication with non-EU regulatory authorities, especially the US FDA, on pharmacovigilance related matters • further develop and implement the electronic transmission and management of pharmacovigilance information